万达生物制药宣布美国FDA受理Imsidolimab治疗泛发性脓疱型银屑病的生物制品许可申请

美股速递
Feb 25

万达生物制药近日宣布,其针对泛发性脓疱型银屑病治疗的生物制剂Imsidolimab的生物制品许可申请,已获得美国食品药品监督管理局的正式受理。这一进展标志着该药物向获批上市迈出了关键一步。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10